Free Trial

Sera Prognostics Q1 2024 Earnings Report

Sera Prognostics logo
$3.54 -0.36 (-9.23%)
As of 03/28/2025 04:00 PM Eastern

Sera Prognostics EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Sera Prognostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sera Prognostics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Sera Prognostics Earnings Headlines

The Dirty Secret About Gold Mining Stocks...
Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.
TD Cowen Sticks to Its Buy Rating for Sera Prognostics (SERA)
See More Sera Prognostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sera Prognostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sera Prognostics and other key companies, straight to your email.

About Sera Prognostics

Sera Prognostics (NASDAQ:SERA), a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

View Sera Prognostics Profile

More Earnings Resources from MarketBeat